D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Patient-Derived Xenografts for Investigation of Acquired Resistance in Oncogene-Driven Cancers: Building a Better Mousetrap
TL;DR: The data suggest that advanced stage NSCLC, both EGFR-mutated and nonmutated, has a higher rate of successful PDX formation, and the ability of PDX models to predict sensitivity and resistance to therapeutic intervention has not yet been fully vetted and requires further validation.
Journal ArticleDOI
Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma.
Christopher M. Mahaffey,Christopher M. Mahaffey,Nichole Mahaffey,W. S. Holland,Hongqiao Zhang,David R. Gandara,Philip C. Mack,Henry Jay Forman +7 more
TL;DR: Direct involvement between the transcription factor Nrf2 and the MRP3 promoter, which leads to the up-regulation of the MRp3 gene is demonstrated.
Journal ArticleDOI
Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC).
Suresh Senan,Anthony Brade,Luhua Wang,Johan Vansteenkiste,Shaker R. Dakhil,Bonne Biesma,Maite Martinez Aguillo,Joachim G.J.V. Aerts,Ramaswamy Govindan,Belén Rubio-Viqueira,Conrad R. Lewanski,David R. Gandara,Hak Choy,Tony Mok,Anwar Hossain,Neill Iscoe,Joseph Treat,Andrew Koustenis,Nadia Chouaki,Everett E. Vokes +19 more
TL;DR: This superiority trial was designed to achieve 80% power, assuming an OS HR of 0.74 with 355 events at 0.05 α (two-sided) using a log-rank test.
Journal ArticleDOI
[Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012].
TL;DR: Evolving Treatment Algorithms for Advanced Non–Small-Cell Lung Cancer: 2009 Looking Toward 2012 David R. GANDARA, Philip C. MACK, Tianhong LI, Primo N. LARA, JR, Roy S. Lara, JR.
Journal ArticleDOI
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
Natasha B. Leighl,Mary W. Redman,Naiyer A. Rizvi,Fred R. Hirsch,Philip C. Mack,Lawrence H. Schwartz,James L. Wade,William J. Irvin,Sreekanth Reddy,Jeffrey Crawford,Jeffrey D. Bradley,Thomas E. Stinchcombe,Suresh S. Ramalingam,Jieling Miao,Katherine Minichiello,Roy S. Herbst,Vassiliki A. Papadimitrakopoulou,Karen Kelly,David R. Gandara +18 more
TL;DR: In this article, the authors evaluated the immunotherapy combination of durvalumab and tremelimumab to overcome resistance to anti-programmed death ligand 1 (PD-(L)1) therapy in patients with advanced squamous lung carcinoma (sq non-small-cell lung cancer).